Quantcast

Latest P53 Stories

2010-12-15 15:44:45

In studies conducted on the fruit fly, researchers at IRB Barcelona headed by ICREA Professor Marco Milán have revealed that organs have the molecular mechanisms to control their proportions. In this process the protein p53 plays a crucial role. The study is published today in the prestigious journal PLoS Biology. The correct establishment of organ proportions, which occurs during embryonic development, is vital for the proper function of all organisms. Alterations in the mechanisms...

2010-12-14 15:24:50

A close collaboration between researchers at the Salk Institute for Biological Studies and the Institute for Advanced Study found that the tumor suppressor p53, long thought of as the "Guardian of the Genome," may do more than thwart cancer-causing mutations. It may also prevent established cancer cells from sliding toward a more aggressive, stem-like state by serving as a "Guardian against Genome Reprogramming." The new work, reported by Geoffrey M. Wahl, Ph.D., and Benjamin Spike, Ph.D., at...

2010-12-07 15:40:00

First clinical trial looks at RG7112 as a way to disable MDM2 in leukemia A pioneering clinical trial is testing the effectiveness in leukemia of a small molecule that shuts down MDM2, a protein that can disable the well-known tumor suppressor p53. Michael Andreeff, M.D., Ph.D., professor of Medicine and chief of Molecular Hematology and Therapy in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, presented preliminary results of this ongoing Phase I study at...

2010-11-17 07:48:33

(Ivanhoe Newswire)-- Although p53 is called the "guardian of the genome", having the job of preventing defective cells from dividing, some cancer cells have found a loop hole. "The critical importance of the protective function of p53 is underscored by the diversity of molecular strategies employed by cancer cells to subvert p53 activity, such as overexpression of antagonistic proteins like HDM2 and HDMX," Dr. Loren D. Walensky, senior study author of Harvard Medical School, was quoted as...

2010-11-16 07:00:00

SAN DIEGO, Nov. 16, 2010 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. will present advances in the development of their first-in-class, CK2 inhibitor CX-4945, at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, to be held on November 16-19 in Berlin, Germany. CX-4945 is the first and only CK2 inhibitor to have entered clinical trials and represents an exciting new approach for the treatment for many different cancers. Three poster presentations will reveal...

2010-11-15 20:40:57

It is common for cancer cells to find some way to disarm p53, also known as "guardian of the genome" due to its action in preventing defective cells from dividing. "The critical importance of the protective function of p53 is underscored by the diversity of molecular strategies employed by cancer cells to subvert p53 activity, such as overexpression of antagonistic proteins like HDM2 and HDMX," explains senior study author Dr. Loren D. Walensky from Harvard Medical School. "Restoration of p53...

2010-10-26 22:15:44

New research links three molecules to a critical tumor suppressor gene that is often turned off in multiple myeloma, a presently incurable cancer of the blood. The findings might offer a new strategy for treating this disease and other blood cancers, according to researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC "“ James) who led the study. The silenced molecules are called miR-192,...

2010-10-21 00:42:47

Sister gene of tumor-suppressor works by regulating the production of micro RNAs Long overshadowed by p53, its famous tumor-suppressing sibling, the p63 gene does the tougher, important job of stifling the spread of cancer to other organs, researchers at The University of Texas MD Anderson Cancer Center report in the Oct. 21 issue of Nature. Not only does a specific form of p63 protein block metastasis, but it does so by activating the enzyme Dicer, which plays a pivotal role in the creation...

2010-10-13 13:39:00

LEXINGTON, Ky., Oct. 13 /PRNewswire/ -- Transposagen Biopharmaceuticals, Inc. (Transposagen), the worldwide leader in genetically modified rats, has announced today that it has entered into an exclusive marketing and distribution agreement with Charles River Laboratories, a leading global provider of research models and services. The license includes two of Transposagen's high-value TGEM(TM) Knockout Rat Models, one rat line contains a mutation in the p53 gene, the most studied tumor...

2010-09-30 19:39:26

New hypothesis in the FASEB Journal suggests balance between NF-kB and p53 signaling is a promising target for new drugs A new report published in the October 2010 print issue of The FASEB Journal (http://www.fasebj.org) offers a ray of hope in the search for new cancer drugs. By examining the seemingly conflicting roles of how oncogenes and tumor suppressor genes handle cellular stress, scientists from the Institute for Advanced Studies in New Jersey argue that each of these opposing systems...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related